TSR1

Across TCGA pan-cancer cohorts, TSR1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TSR1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TSR1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TSR1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where TSR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.709	0.926	.001	42	view →
LSCC	DFS	Median	II,III,IV	0.858	0.517	<.001	28	view →
CCRCC	OS	Tertile	All	0.709	0.900	.006	25	view →
LUAD	DFS	Median	III,IV	0.977	0.504	.005	18	view →
UCEC	DFS	Quartile	All	0.778	1.000	.003	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TSR1–PDAC (OS)

Open the PDAC breakdown →